Form 4: TriSalus Life Sciences Director Mats Wahlstrom Increases Stake Through Open Market Purchases

Director Mats Wahlstrom of TriSalus Life Sciences has increased his holdings through open market purchases of common stock.

Summary

• Mats Wahlstrom, a director at TriSalus Life Sciences, has acquired additional shares of the company's common stock.
• On November 20, 2024, he purchased 2,040 shares at a weighted average price of $4.16 per share.
• On November 21, 2024, he purchased 8,687 shares at a weighted average price of $4.44 per share.
• These transactions increased his direct holdings to 10,727 shares.
• Wahlstrom also has indirect ownership of 1,254,259 shares through Leonard Capital LLC and 1,370,028 shares through HW Investment Partners, LLC.
• He shares voting and investment discretion with his spouse regarding the shares held by Leonard Capital LLC.
• He is a managing member of HW Investment Partners, LLC and shares voting and investment discretion with respect to the shares held by HW Investment.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the director's open market purchases suggest confidence in the company's prospects. However, it's a routine filing and not a major event.

Positives

• The director's open market purchases indicate confidence in the company's future prospects.
• The increased stake demonstrates a commitment to the company's success.

Industry Context

This filing is a routine disclosure of insider trading activity, which is common in publicly traded companies. It provides transparency into the actions of company directors and their investment decisions.

Comparison to Industry Standards

• Insider trading disclosures are a standard practice for all publicly listed companies, and this filing is consistent with those requirements.
• The level of detail provided in this Form 4 is typical, including the number of shares purchased, the price per share, and the nature of ownership (direct or indirect).
• Similar filings can be seen across the biotechnology and pharmaceutical industries, where directors and officers often hold significant stakes in their companies.

Stakeholder Impact

• The increased stake by a director may be viewed positively by shareholders, potentially increasing confidence in the company.
• The purchases do not have a direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

TriSalus Life Sciences, Mats Wahlstrom, insider trading, share purchase, common stock, director, TLSI, beneficial ownership